Retatrutide has emerged as a new medication in the fight against obesity. This groundbreaking drug, categorized as a dual GLP-1 and GIP receptor agonist, shows promising results in research studies. By stimulating these receptors, Retatrutide controls cravings, {promotesglucose regulation, and ultimately contributes to significant reduction in body